Pomerantz Law Firm Launches Investigation for Valneva SE Investors Amid Concerns of Fraud

Legal Cloud Over Valneva SE

The Pomerantz Law Firm has initiated an investigation for investors of Valneva SE (NASDAQ: VALN), focusing on allegations of potential securities fraud and other illegal activities by the company and its executives. This comes amid troubling reports about Valneva’s chikungunya vaccine, IXCHIQ, fueling significant investor concerns.

In February 2025, the U.S. Centers for Disease Control and Prevention (CDC) announced that it was investigating five hospitalizations involving cardiac or neurological issues following IXCHIQ vaccinations in individuals aged 65 and older. This news led to an immediate decline of Valneva's American Depositary Receipt (ADR), which dropped by over 13% within a few trading sessions.

As if that wasn't enough, in August 2025, the U.S. Food and Drug Administration (FDA) announced a suspension of the marketing application for IXCHIQ due to emerging safety concerns. Following this announcement, Valneva's ADR price experienced a notable decline, plummeting by nearly 19%.

The rapid depletion in stock value has raised alarm bells among investors, prompting Pomerantz LLP to step in. The firm, well-regarded in the realms of corporate and class action litigations, has a rich history of assisting victims of securities fraud. Founded by Abraham L. Pomerantz, known as a pioneer in the class action realm, the firm continues to uphold his legacy by championing the rights of those wronged by corporate misconduct.

Investors of Valneva are advised to take action—contacting Danielle Peyton at Pomerantz LLP for guidance on how to navigate this turbulent period. The firm is keen on unearthing the truth behind the reported allegations and seeks to protect the interests of its clients.

As the investigation unfolds, all eyes will be on Valneva SE. With its recent vaccine trials under scrutiny, the outcome of this situation could have far-reaching implications not just for the company's future prospects but also for those who closely invested in its journey.

In the wake of federal investigations and stock price volatility, there lies a pivotal moment for Valneva and its stakeholders. Investors are urged to remain vigilant as further updates from Pomerantz LLP are anticipated.